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Genome-wide DNA methylation analysis on C-reactive
protein among Ghanaians suggests molecular links to the
emerging risk of cardiovascular diseases
Felix P. Chilunga 1✉, Peter Henneman2, Andrea Venema2, Karlijn A. C. Meeks 3, Ana Requena-Méndez4,5, Erik Beune1,
Frank P. Mockenhaupt6, Liam Smeeth7, Silver Bahendeka8, Ina Danquah9, Kerstin Klipstein-Grobusch10,11, Adebowale Adeyemo 3,
Marcel M.A.M Mannens2 and Charles Agyemang1
Molecular mechanisms at the intersection of inflammation and cardiovascular diseases (CVD) among Africans are still unknown. We
performed an epigenome-wide association study to identify loci associated with serum C-reactive protein (marker of inflammation)
among Ghanaians and further assessed whether differentially methylated positions (DMPs) were linked to CVD in previous reports,
or to estimated CVD risk in the same population. We used the Illumina Infinium® HumanMethylation450 BeadChip to obtain DNAm
profiles of blood samples in 589 Ghanaians from the RODAM study (without acute infections, not taking anti-inflammatory
medications, CRP levels < 40mg/L). We then used linear models to identify DMPs associated with CRP concentrations. Post-hoc, we
evaluated associations of identified DMPs with elevated CVD risk estimated via ASCVD risk score. We also performed subset
analyses at CRP levels ≤10mg/L and replication analyses on candidate probes. Finally, we assessed for biological relevance of our
findings in public databases. We subsequently identified 14 novel DMPs associated with CRP. In post-hoc evaluations, we found
that DMPs in PC, BTG4 and PADI1 showed trends of associations with estimated CVD risk, we identified a separate DMP in MORC2
that was associated with CRP levels ≤10mg/L, and we successfully replicated 65 (24%) of previously reported DMPs. All DMPs with
gene annotations (13) were biologically linked to inflammation or CVD traits. We have identified epigenetic loci that may play a role
in the intersection between inflammation and CVD among Ghanaians. Further studies among other Africans are needed to confirm
our findings.
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INTRODUCTION
Cardiovascular diseases (CVD) are rapidly becoming the leading
causes of morbidity and mortality among African populations1.
Changes in life-style factors (e.g. tobacco smoking, poor diet and
physical inactivity) are prominent contributors to the emerging
risk of cardiovascular diseases (CVD). However, these factors do
not fully account for the growing burden of CVD2.
Chronic inflammation is currently seen as an important factor in
the pathogenesis of CVD3,4. The link between inflammation and
CVD is complex with several molecular pathways identified5. One
such pathway is via epigenetic modifications, which are heritable
yet reversible molecular modifications to DNA, which can affect
phenotypic expression without altering the DNA sequence6. DNA
methylation (DNAm) is the most studied and best understood
epigenetic modification6. It is affected by environment changes
such as inflammation and modulates gene expression via the
regulation of transcription factor binding and attraction of methyl-
binding proteins that initiate chromatin compaction and gene
silencing6. As such, studies among populations from high income
countries (HIC) have identified DNAm sites that link inflammation
to CVD7.
Although African populations may be exposed to similar
triggers of inflammation as in HIC populations such as adiposity,
heterogeneity in genotype and other inflammatory factors
prevalent among Africans, such as intestinal parasites, chronic
infections (HIV and Mycobacterium Tuberculosis), and other
tropical diseases, may alter epigenetic pathways that are dissimilar
to those of populations from HIC8,9. A small study attempted to
unravel the epigenetic mechanisms of inflammation among black
South African men but was underpowered to detect any
differentially methylated sites10. As a result, little is known about
epigenetic mechanisms linking chronic inflammation and CVD in
African populations.
C-reactive protein (CRP) is a sensitive marker of inflammation
and has been associated with increased risk of coronary heart
disease, stroke and vascular mortality in population based
studies11,12. We, therefore, performed an epigenome-wide asso-
ciation study (EWAS) to identify differentially methylated loci
associated with CRP among Ghanaians. Subsequently, we
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assessed whether these detected loci were associated with the 10-
year estimated risk of CVD in the same population, or with CVD in
previous genome/epigenome-wide association studies13,14.
RESULTS
Baseline characteristics
A total of 589 participants were included in the current analysis. Of
these, 313 (53.1%) resided in Europe, while 276 (46.9%) resided in
Ghana, which is in line with the general RODAM population. The
mean age was 51 ± 18 years. The majority (55%) were female. The
median CRP level was 0.80 (IQR 0.30–2.80). Those with elevated
CRP (>3mg/L) were likely to have higher BMI, to have diabetes
and to have elevated 10-year predicted CVD risk and to have a
lower estimated CD4 T-cell count (Table 1).
Differentially methylated positions and regions
DNAm levels of 14 CpG sites showed genome-wide significant
associations with CRP at 5% FDR (Table 2, Fig. 1). These DMPs
included; cg14653250 in TSS200 (transcription start site) of PC,
cg02338947 in 3′UTR (untranslated region) of FAM124B,
cg01573121 in 5′UTR of DNAJC28, cg12144754 in 1stExon of
PRPS1L1, cg26859186 in the body of PTPRN2, cg19712490 in
TSS200 of CD81, cg12842013 in 1stExon of HOMEZ, cg01099220
in 3′UTR of LRRC14, cg25806492 in body of SRRM1, cg13767940 in
TSS200 of BTG4, cg21010178 in TSS1500 of PADI1, cg22602019 in
3′UTR of FAM167B and cg13198133 in the intergenic region and
cg02150674 in TSS200 of PHYH as per Illumina platform
annotations (IlluminaHumanMethylation450kanno.ilmn12.hg19).
DNAm variation in these DMPs ranged from 0.04% (cg02150674)
to 0.4% (cg02338947) with each unit increase in CRP (mg/L), Table
2, Supplementary Fig. 1). Our statistical analyses did not return any
DMRs using bumphunter.
Post-hoc findings
First, we performed a replication analysis on 280 DMPs that were
identified in a multi-ethnic EWAS meta-analysis on CRP on
populations from HIC (Supplementary Table 1). While eight out
of these 280 candidates could not be evaluated in our data
(removed during quality control), the rest (272) were not part of
our top 14 genome-wide significant DMPs. Performing linear
regression on these 272 candidates, we identified 66 candidate
probes with p < 0.05. Except for one probe (cg22959742), the rest
of the probes (65) had similar direction of effects as in the multi-
ethnic EWAS meta-analysis on CRP. Thus, we replicated 24% (65/
272) of the DMPs based on consistency of direction of effect
(Supplementary Table 2).
Second, we performed sensitivity analyses on obesity and type
2 diabetes (T2D; Supplementary Fig. 2). We found that our top 14
genome-wide significant DMPs were also detectable in sensitivity
analyses that excluded BMI and T2D as covariates in linear
regression models. In addition, we found strong correlations
between delta-beta values (r= 0.99), and between p-values (r=
0.81) in the main analysis in relation to the sensitivity analyses.
Moreover, none of the top 14 genome-wide significant DMPs was
reported in previous EWAS on obesity and T2D in the same study
population15,16.
Third, we performed sensitivity analyses on location of
residence (Supplementary Table 3 and Supplementary Fig. 3).
With regards to our top 14 genome-wide significant DMPs, we
detected some slight differences in delta-beta values between
Ghanaians resident in Ghana and Ghanaians resident in Europe.
For instance, the delta-beta values for cg14653250 (PC),
cg01573121 (DNAJC28), cg12842013 (HOMEZ), cg25806492
(SRRM1), cg13767940 (BTG4) and cg21010178 (PADI1) were slightly
higher in Ghanaians resident in Europe as compared to Ghanaians
resident in Ghana, while those for cg12144754 (PRPS1L1),
cg26859186 (PTPRN2), cg19712490 (CD81), cg22602019
(FAM167B), cg13198133 (intergenic) and cg02150674 (PHYH) were
slightly higher in Ghanaians resident in Ghana compared to
Ghanaians resident in Europe. We did not detect any differences in
delta-beta values in cg02338947 (FAM124B) and cg01099220
(LRRC14) between Ghanaians resident on the two continents.
However, all 14 genome-wide significant DMPs were still
detectable in sensitivity analyses that included migration status
as a covariate in linear regression models. Characteristically, delta-
beta values in the main analysis were strongly correlated to those
in sensitivity analysis (r= 0.99). Such strong correlations were also
observed for p-values (r= 0.99).
Fourth, we examined DNAm differences at CRP levels ≤10mg/L
(Supplementary Figs. 4, 5, Supplementary Table 4). This was
achieved by performing a subset analyses on 549 participants with
CRP levels ≤10mg/L. DNAm levels at one CpG site (cg02551882 in
TSS1500 of MORC2 gene) showed genome-wide significant
associations with CRP concentrations ≤10mg/L at 5% FDR. It
had a delta-beta value of 0.04% for each unit increase in CRP
concentration (mg/L).
Fifth, we investigated the link between DNAm variations in CRP
and estimated cardiovascular risk (Table 3). This was achieved by
assessing whether DNAm in genome-wide significant DMPs was
associated with estimated CVD risk in a sub-sample of participants
with ASCVD risk scores (n= 472 eligible based on ASCVD criteria)
at 5% FDR. Although three probes (cg14653250 in PC, cg13767940
in BTG4, cg21010178 in PADI1) showed trends of associations with
estimated CVD risk (FDR 0.07–0.08), none of the genome-wide
significant DMPs demonstrated statistical significance at an FDR
threshold of <0.05 in these particular analyses.
Sixth, we investigated biological relevance of our findings with
respect to gene expression, and links to inflammation and CVD
traits in public databases (Table 4, Supplementary Tables 5–8). We
first evaluated the link between genome-wide significant DMPs
and gene expression in IMETHYL database. We found that lower
DNAm in 5′UTR of DNAJC28 (cg01573121), and in TSS of PC
(cg14653250), PHYH (cg02150674) and MORC2 (cg02551882) were
associated with higher expression of the respective genes, while
higher DNAm in the body PTPRN2 (cg26859186) and HOMEZ
(cg12842013), and in 3′UTR of FAM167B (cg22602019) were
associated with higher expression of respective genes. This
pattern was not observed in the remaining DMPs. Next, we
assessed whether genes annotated to statistically significant DMPs
were enriched to discrete pathways in KEGG and GO databases
using MissMethyl package at 5% FDR. Both KEGG and GO
databases did not yield any statistically significant pathways.
However, the pathways that were observed at higher FDR (>5%)
included adaptive immune response, CD4-positivity, alpha-beta T-
cell stimulation, methyl-branched fatty acid metabolic process,
fatty acid biosynthesis, B-cell receptor signaling pathway, Hepatitis
C and metabolic pathways which seem biologically plausible in
the context of our study since these pathways are related to
chronic inflammation. Finally, we searched in genome -wide
association studies (GWAS) catalog (https://www.ebi.ac.uk/gwas/),
GeneCards (https://www.genecards.org/) and EWAS catalog
(http://ewascatalog.org/) to determine whether variants in genes
annotated to statistically significant DMPs were linked to
inflammation or CVD traits. We found that all genome-wide
significant DMPs with gene annotations (13) were linked to
inflammation or CVD factors such as markers of inflammation
(interferons, interleukins, platelet-derived growth factors, leuko-
cyte count, fibrinogen), chronic inflammatory diseases (HIV
infections, allergies/asthma, autoimmune diseases) and cardiome-
tabolic factors (cholesterol levels, Apo lipoproteins, blood
pressure, carotid plaque build, coronary artery calcification,
N-terminal pro-B-type natriuretic peptide and incident CVD).
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We identified 14 novel DMPs associated with CRP levels up to
40mg/L in Ghanaians without acute infections or taking anti-
inflammatory medications. In post-hoc evaluations, we found that
DMPs in PC, BTG4 and PADI1 showed trends of associations with
estimated CVD risk, we identified a separate DMP in MORC2 that
was associated with CRP levels ≤10mg/L, and we successfully
replicated 65 (24%) of previously reported CRP associated DMPs.
All DMPs with gene annotations (13) were biologically linked to
inflammation or CVD traits.
In our study of DNAm variations associated with CRP in
Ghanaians without acute infections or taking anti-inflammatory
medications, we had postulated that epigenetic pathways may be
dissimilar to those of populations from HIC. This would potentially
be due to heterogeneity in genotype between Africans and
population from HIC17, as well as to differences in inflammatory
factors that may be prevalent in each population. For example,
intestinal parasites, chronic infections (HIV, Hepatitis C and
Mycobacterium Tuberculosis) and other tropical diseases may be
common among Africans than in populations from HIC8,9.
Moreover, chronic infections that have higher prevalence in
Africans than in populations from HIC (e.g. HIV, Hepatitis C, etc.)
are known to raise CRP concentration to >10mg/L18, which was
the basis for inclusion of CRP levels up to 40 mg/L in our study
(acute bacterial infections are mostly the cause after this thresh-
old)18. This is in contrast to populations from HIC who might have
less of these infections19.












Age, mean (SD)c 51.18 (9.87) 50.17 (9.40) 51.92 (10.31) 52.62 (10.21) 0.009
Sex (female), n (%) 324 (55.01) 146 (47.71) 81 (56.64) 97 (69.29) <0.001
Location 0.222
Rural Ghana 76 (12.90) 34 (11.11) 20 (13.98) 22 (15.71)
Urban Ghana 200 (33.96) 99 (32.35) 46 (32.17) 55 (39.29)
European Ghanaians 313 (53.14) 173 (56.54) 77 (53.85) 63 (45.00)
Education, n (%) 0.032
Elementary 186 (31.57) 94 (30.72) 47 (32.87) 45 (32.14)
Primary 244 (41.42) 114 (37.25) 70 (48.95) 60 (42.86)
Secondary 102 (17.32) 63 (20.59) 19 (13.29) 20 (14.29)
Tertiary 57 (9.67) 35 (11.44) 7 (4.90) 15 (10.71)
Smoking, n (%) 0.436
Current 15 (2.55) 5 (1.63) 6 (4.20) 4 (2.86)
Past 58 (9.85) 34 (11.11) 13 (9.09) 11 (7.86)
Alcohol consumption, mean (SD)d 0.21 (0.85) 0.21 (0.79) 0.31 (1.23) 0.09 (0.29) 0.369
Diabetes, n (%) 210 (35.65) 85 (27.78) 52 (36.36) 73 (52.14) <0.001
BMI, mean (SD)e 27.02 (5.59) 25.42 (4.66) 27.91 (5.43) 29.62 (6.44) <0.001
Elevated CVD risk, n (%)f 281 (47.70) 136 (44.44) 68 (47.55) 77 (55.00) 0.017
Systolic BP, mean (SD)f 134.97 (20.68) 133.89 (19.79) 137.17 (22.89) 135.09 (20.17) 0.399
Use of anti-hypertensives, n (%)f 68 (24.19) 41 (30.14) 12 (17.64) 15 (19.48) 0.147
Total cholesterol, mean (SD)f 5.23 (1.21) 5.07 (1.04) 5.37 (1.45) 5.46 (1.21) <0.001
HDL cholesterol, mean (SD)f 1.34 (0.38) 1.39 (0.40) 1.32 (0.37) 1.23 (0.32) <0.001
Cell counts in %
CD4 T cells, mean (SD) 18.18 (5.65) 18.31 (5.48) 18.87 (5.49) 17.17 (6.07) 0.107
CD8 T cells, mean (SD) 10.73 (4.75) 10.99 (5.11) 10.34 (4.44) 10.58 (4.20) 0.013
Natural killer cells, mean (SD) 10.80 (5.50) 11.14 (5.54) 10.64 (5.50) 10.21 (5.58) 0.089
B cells, mean (SD) 10.60 (3.44) 10.67 (3.33) 10.74 (3.70) 10.29 (3.42) 0.352
Monocytes, mean (SD) 8.01 (2.42) 7.75 (2.16) 8.15 (2.77) 8.43 (2.50) 0.004
Granulocytes, mean (SD) 45.41 (9.04) 44.82 (9.16) 45.08 (8.85) 47.01 (8.81) 0.026
CRP, median (IQR)g 0.80 (0.30–2.80) – – – –
CRP ≤ 10mg/L, n (%) 549 (93%) – – – –
aCRP levels categorized according to American Heart Association categories: <1mg/L= low, 1 to 3mg/L= borderline, >3 mg/L= Elevated.
bP-value for differences in means.
cAge is measured in years.
dAlcohol consumption in units per day.
eBMI= Body mass index presented in Kg/m2 as mean with standard deviation.
f10-year risk of CVD estimated using the Pooled Cohort Equations. Variables used for the estimation include age, sex, total cholesterol, high-density lipoprotein
cholesterol, systolic BP, use of antihypertensive medication, diagnosed with diabetes mellitus and smoking. Low CVD risk <7.5%, Elevated CVD risk ≥7.5%. In
this subset, N= 472. Proportion of the most abundant cells was estimated using the method by Houseman et al.60
gHigh sensitivity-C-reactive protein (CRP) measured in mg/L.
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Subsequently, we identified 14 novel DMPs that were
associated with CRP concentrations up to 40mg/L in Ghanaians
without acute infections or taking anti-inflammatory medications.
Of these DMPs, 13 were annotated to genes, such as PC, FAM124B,
DNAJC28, PRPS1L1, PTPRN2, CD81, HOMEZ, LRRC14, SRRM1, BTG4,
PADI1, FAM167B and PHYH. DNAm in these 13 genes was generally
in line with gene expression trends reported in literature, whereby
higher DNAm in the promoter region was associated with lower
gene expression and higher DNAm in the gene body was
associated with higher gene expression20. While these genes
have various functions in the human body, the genes CD81 and
LRRC14 have specific inflammation related functions. Specifically,
the gene CD81 encodes a protein that plays a role in the
regulation of cell development and motility in interleukin 2 (IL-2)
pathway21. IL-2 has essential roles in key functions of the immune
system, primarily via its direct effects on T cells22. On the other
hand, LRRC14 gene encodes a leucine-rich repeat-containing
protein, which negatively regulates a toll-like receptor-mediated
nuclear factor-kappa-B (NF-κB) signaling21. NF-κB is a major
transcription factor that regulates genes responsible for both
the innate and adaptive immune response23. Despite only two
genes (of the 13) having immune related functions, previous
EWAS and GWAS have shown that all 13 genes are linked to
inflammatory traits. For instance, genomic/epigenomic variation in
PC and SRRM1 was associated with HIV infection and rheumatoid
arthritis24,25, in FAM124B with monokine induced by gamma
interferon26, in DNAJC28 with ulcerative colitis and crohn’s
disease27, in PRPS1L1 with fibrinogen levels28, in PTPRN2 with
atopic eczema and inflammatory bowel disease25,29, in CD81 with
systemic scleroderma and monocyte count30,31, in HOMEZ with
HIV infection24, in LRRC14 with neutrophils and eosinophil
counts30, in BTG4 with IL-4 levels26, in PADI1 with serum 25-
Hydroxyvitamin D levels32, in FAM167B with rheumatoid arthritis25
and in PHYH with allergies33. It is therefore possible that DNAm
variations in these genes plays a role in chronic inflammation
among Ghanaians. On the other hand, a single DMP (cg13198133)
was intergenic with no deoxyribonuclease (DNase) sensitivity
markers in its vicinity (i.e. no evidence of links to gene expression
in cis) and has not been reported in previous EWAS. It is not clear
whether this probe is biologically meaningful with respect to
chronic inflammation.
The other goal of our study was to ascertain the link between
DNAm variations in CRP and CVD among Ghanaians. Although all
14 genome-wide significant DMPs did not reach the statistical
criteria for detecting associations between DNAm and estimated
CVD risk (FDR < 0.05), DNAm variation in probes annotated to PC,
BTG4 and PADI1 genes showed some trends of association (FDR
0.07–0.08). While BTG4 and PADI1 do not have CVD related
functions, the PC gene encodes pyruvate carboxylase, an
important enzyme in gluconeogenesis, lipogenesis and insulin
secretion34. Deregulation of PC expression has been associated
with T2D, which is a major risk factor for CVD and an important
component of the CVD risk prediction algorithm35. Furthermore,
previous GWAS and EWAS have shown that variants in all three
genes are linked to CVD risk factors. For example, variants in PC
have been associated with proinsulin levels, urate levels and waist-
to-hip ratio36,37, in BTG4 with waist-to-hip ratio and IL-4 (pro-
inflammatory on vascular endothelium and may play a critical role
in the development of atherosclerosis)26,37, and in PADI1 with
dietary patterns38. It is therefore possible that DNAm variations in
these three genes may also contribute to CVD risk in Ghanaians.
Additionally, some DMPs, which did not show associations with
estimated CVD risk in Ghanaians, have been previously linked to
CVD. For instance, variants in FAM124B, PTPRN2, SRRM1 have been
associated with platelet-derived growth factors (atherosclerotic
pathways)26, carotid plaque buildup and strokes39,40 and incident
CVD, respectively, in previous EWAS and GWAS41. Since our
analysis was based on estimated CVD risk (which might vary from
actual incident CVD after 10 years), future studies should assess
whether DNAm in these genes could also affect incident CVD in
Ghanaians.
Due to environmental differences in Europe and Ghana, which
might uniquely affect CRP levels in each context9, we assessed
whether location of residence in Ghana or in Europe among our
Ghanaians participants influenced our findings. While we found
very tiny differences in effect sizes (delta-beta values) between
Table 2. List of differentially methylated positions associated with CRP among Ghanaians.
No CpG ID Chromosome Positiona Gene namea Featurea Relation to Islanda Delta β valueb P-value FDR
1 cg14653250 chr11 66725860 PC TSS200 Island 5.31E-04 2.51E-12 1.1E-06
2 cg02338947 chr2 225244102 FAM124B 3′UTR OpenSea −4.47E-03 6.36E-11 1.4E-05
3 cg01573121 chr21 34863117 DNAJC28 5′UTR N_Shore −1.32E-03 1.64E-10 2.4E-05
4 cg12144754 chr7 18067437 PRPS1L1 1stExon OpenSea −9.53E-04 5.63E-10 6.0E-05
5 cg26859186 chr7 157351708 PTPRN2 Body N_Shore −1.61E-03 2.91E-09 2.5E-04
6 cg19712490 chr11 2398477 CD81 TSS200 Island 2.32E-03 6.41E-09 4.6E-04
7 cg12842013 chr14 23755227 HOMEZ 1stExon Island 4.33E-04 1.33E-08 8.1E-04
8 cg01099220 chr8 145747659 LRRC14 3′UTR Island 1.26E-03 2.38E-08 1.3E-03
9 cg25806492 chr1 24970113 SRRM1 Body Island 1.57E-03 3.03E-08 1.4E-03
10 cg13767940 chr11 111383603 BTG4 TSS200 Island 2.15E-03 6.06E-08 2.5E-03
11 cg21010178 chr1 17530227 PADI1 TSS1500 OpenSea −1.93E-03 6.35E-08 2.5E-03
12 cg22602019 chr1 32714308 FAM167B 3′UTR S_Shore 9.00E-04 8.12E-08 2.9E-03
13 cg13198133 chr10 132453765 Intergenic Intergenic OpenSea −2.92E-03 1.10E-07 3.4E-03
14 cg02150674 chr10 13342205 PHYH TSS200 Island 4.94E-04 1.15E-07 3.4E-03
TSS1500 transcription start site 1500 (the region from Transcription start site (TSS) to −1500 nucleotides upstream of TSS), 5′UTR 5′ untranslated region (the
region of an mRNA that is directly upstream from the initiation codon), 3′UTR 3′ untranslated region (the region of an mRNA that is downstream from the stop
codon), TSS200 transcription start site 200 (the region from Transcription start site (TSS) to −200 nucleotides upstream of TSS), FDR false discovery rate (a 5%
FDR is considered significant).
aAnnotation were perfomed via IlluminaHumanMethylation450kanno.ilmn12.hg19. Homo sapiens (human) genome assembly GRCh37 (hg19)61.
bDelta β-value of DNA methylation against each unit increase in CRP (mg/L) derived from linear regression models adjusted for age, sex, array, plate position,
alcohol consumption, smoking, BMI, type 2 diabetes and proportion of immune cells (N= 589).
F.P. Chilunga et al.
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Ghanaians resident in Ghana and Ghanaians resident in Europe in
several DMPs (i.e. those annotated to PC, DNAJC28, PRPS1L1,
PTPRN2, CD81, HOMEZ, SRRM1, BTG4, PADI1 and FAM167B genes),
the effects were still apparent and unchanged after adjusting for
location of residence in the main analyses. This shows that
location of residence did not exert any influence on our findings.
Since our study had included CRP concentrations up 40mg/L
(mostly seen in persons with chronic diseases as regards to
chronic inflammation)42, we performed a subset analysis at CRP
levels ≤10mg/L (mostly seen in healthy adults and represent
metabolic inflammation)43. We identified cg02551882 in the
promoter region of MORC2 to be associated with CRP levels
≤10mg/L, with a delta-beta value of 0.04% for each unit increase
in CRP (mg/L). Higher DNAm in cg02551882 was associated with
lower gene expression in MORC2 per IMETHYL database. The
MORC2 gene encodes a protein that regulates condensation of
heterochromatin in response to DNA damage and plays a role in
transcription repression21. This protein also plays a role in
lipogenesis and adipocyte differentiation44. Moreover, previous
EWAS and GWAS have shown that variants in MORC2 are
associated with metabolic inflammatory traits such as BMI, T2D
and coronary artery calcification45,46, as well as non-metabolic
inflammatory traits such as eosinophil count and primary
Sjogren’s syndrome41,47. Our findings therefore show that DNAm
methylation aberrations in CRP among Ghanaians are more
apparent at chronically elevated CRP levels beyond 10mg/L (14
DMPs) than below this threshold (one DMP). Further studies
should characterize the specific conditions that lead to CRP levels
beyond 10mg/L in Ghanaians48, which should then in turn be
routinely screened and treated to prevent CVD sequelae from
DNAm aberrations.
We discovered that the effects sizes (delta-beta values) were
relatively small for the statistically significant DMPs. This is not
surprising considering that the effect sizes in the previous EWAS
meta-analysis of CRP (N > 12,000) were in the same range
(0.0011–0.01)7. Moreover, such small DNAm differences in the
EWAS meta-analysis were correlated with gene expression in cis7.
This suggests that our findings may be biologically meaningful
with respect to inflammation or CVD pathogenesis.
We were able to replicate 24% of previously reported DMPs
from European and African American populations. This demon-
strates that some DNAm aberrations associated with CRP
concentrations are similar across populations. However, our
findings also suggest that majority of DNAm alterations in CRP
vary according to ethnicity (genetic heterogeneity), or due to
environmental context (prevalent inflammatory triggers). More
importantly, the role of ethnicity and context was corroborated by










Fig. 1 Manhattan plot of DMPs associated with CRP among Ghanaians. All 429,459 CpG sites are presented according to p-value in EWAS, as
well as by chromosomal annotation. Red line is the demarcation line for statistically significant DMPs at p < 1.1E-7.
Table 3. Associations between DNA methylation in genome-wide







cg14653250 PC TSS200 0.0028 0.005 0.071
cg02338947 FAM124B 3′UTR 0.0023 0.726 0.848
cg01573121 DNAJC28 5′UTR −0.0004 0.872 0.920
cg12144754 PRPS1L1 1stExon 0.0019 0.294 0.515
cg26859186 PTPRN2 Body 0.0016 0.464 0.650
cg19712490 CD81 TSS200 −0.0059 0.209 0.421
cg12842013 HOMEZ 1stExon 0.0009 0.205 0.421
cg01099220 LRRC14 3′UTR −0.0003 0.919 0.920
cg25806492 SRRM1 Body 0.0034 0.210 0.421
cg13767940 BTG4 TSS200 0.0098 0.016 0.084
cg21010178 PADI1 TSS1500 −0.0089 0.018 0.084
cg22602019 FAM167B 3′UTR −0.0023 0.208 0.421
cg13198133 Intergenic Intergenic 0.0017 0.698 0.848
cg02150674 PHYH TSS200 −0.0009 0.369 0.575
ASCVD risk American College of Cardiology/American Heart Association
atherosclerotic cardiovascular disease (ACC/AHA ASCVD) risk score as
previously applied in the RODAM study. The risk score is used among
persons aged 40–79 years, without prior history of CVD, using an algorithm
that combines age, sex, use of antihypertensive medication, systolic blood
pressure, presence of T2D, total cholesterol, HDL cholesterol and smoking
status. A score of >7.5% is considered to be an elevated risk of developing
a CVD in the next 10 years based on the prior work by Goff et al.59.
aAnnotation were perfomed via IlluminaHumanMethylation450kanno.
ilmn12.hg19. Homo sapiens (human) genome assembly GRCh37 (hg19)61.
bβ-coefficient from linear regression model of DNA methylation in CRP
(outcome) against estimated risk of cardiovascular diseases adjusted for
alcohol consumption, BMI and proportion of immune cells. N= 472 (281
for elevated CVD risk, 191 for low CVD risk).
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several distinctions in EWAS among ethnicities (in different
environmental contexts) for similar traits10.
The main strength of this study is that it was conducted in
under-represented cohorts such as populations originating from
low- and middle-income countries (LMIC). This study, therefore,
adds to the much-needed evidence on DNAm and inflammation
in African populations. Our study has several limitations. First,
DNAm was measured in blood although the preferable tissue for
CRP is the liver where it is synthesized. Nevertheless, blood has
been demonstrated to be a good surrogate tissue49. Second, the
study sample of DNAm was selected based on obesity and T2D
case-control status, which can influence CRP levels. However, our
sensitivity analyses demonstrated that BMI and T2D did not have
overt influence on our results. Third, we excluded all participants
who could possibly have had acute infections, or were taking anti-
inflammatory medications, or had CRP levels >40 mg/L, but we
cannot exclude that some participants were still missed. Fourth,
genome-wide gene expression data, which could have enhanced
biological interpretation of our results is not available for this
study population. Nonetheless, we utilized the validated IMETHYL
database relating our top probes to gene expression50. This
publicly available database does suggest a link between some of
our loci and gene expression. Fourth, although we removed
probes that hybridized to known SNPs, data on SNPs from Africans
is limited and some of our results could be due to uncharacterized
SNPs in Africans. However, our data did not show any clustering
patterns, which are specific to SNPs51. Fifth, post-hoc analyses that
tested associations between genome-wide significant DMPs and
estimated CVD risk were performed in a subset of participants (n
= 472) and not the total sample in which the DMPs were
identified (n= 589), it is therefore possible that there was
selection bias as DNAm variations associated with CRP were
detected in the total sample. However, those selected for the post-
hoc analyses met the criteria for ASCVD and were more likely to
have CVD in the next 10 years as opposed to those that did not
meet the criteria. Lastly, we cannot fully rule-out residual and
unmeasured confounding due to the cross-sectional nature of our
study design.
Our study provides the first insights into the epigenetic
mechanisms linking chronic inflammation and CVD risk in
Ghanaians. These findings are highly relevant because they
inform our understanding of the etiology of the emerging CVD
among Ghanaians with respect to chronic inflammation. Future
studies are needed to confirm our findings in other African
populations, as well as to elucidate specific causes of chronically
elevated CRP among Ghanaians, which will facilitate screening
and treatment.
METHODS
Study population and sample selection
The study is part of the Research on Obesity and Diabetes among African
Migrants (RODAM) study. The cross-sectional multi-centre RODAM study
was initiated in 2012 with the aim of understanding the complex interplay
between the environment and genetics in the development of obesity and
diabetes among African migrants. The full details of the study have been
published elsewhere52. In brief, the RODAM study enrolled 6385 migrant
Ghanaian men and women residing in Europe and Ghana. In Europe,
participants were recruited from the cities of Amsterdam (NL), Berlin (DE)
and London (UK). In Ghana, recruitment of participants in the urban area
was conducted in two purposively chosen cities (Kumasi and Obuasi),
while recruitment in the rural area was conducted in 15 villages in the
Ashanti region. Participants were included in the present analyses if they
were aged ≥25 years, had completed the questionnaire, were physically
examined and had blood samples taken. For the present study, we used a
subset of the RODAM study for which DNAm data were available (n= 736).
In the primary study, the 736 participants were selected for DNA profiling
based on a case-control design (~300 diabetic cases, ~ 300 controls, ~135
obese controls)15.
From the 736 participants with DNAm data that were available for this
study, 593 participants remained after quality control and excluding
participants with possible acute infections (fever, upper respiratory tract
symptoms, wound care, any illness in the last 2 weeks), and those taking
medications, which may alter CRP levels (immune-modulating agents,
NSAIDS, steroids and statins (potent anti-inflammatory agents)53, Supple-
mentary Fig. 6). While CRP concentrations between 2 and 10mg/L are
considered as metabolic inflammation (i.e. metabolic pathways that cause
arteriosclerosis)43, chronically elevated CRP concentrations >10mg/L have
also been associated with CVD42. This is particularly important in our study
because chronic infections that have higher prevalence in Africans than in
populations from HIC (e.g. HIV and Hepatitis C, etc) are also known to raise
CRP concentration to >10mg/L18. As such, we sought to include
participants with CRP concentrations >10mg/L in our analyses while
Table 4. Relationship between DNA methylation and gene expression as reported in the IMETHYL database.
CpG ID Nearest genea Gene featurea Methylation level b Methylation averageb% (SD) FPKMb,c average(SD)
cg14653250 PC TSS200 Low 0.77 (1.51) 0.61 (0.18)
cg02338947 FAM124B 3′UTR High 84.10 (24.48) −0.42 (0.18)
cg01573121 DNAJC28 5′UTR High 86.66 (8.10) −0.59 (0.15)
cg12144754 PRPS1L1 1stExon High 97.81 (2.43) Data not available
cg26859186 PTPRN2 Body High 96.10 (3.50) 0.27 (0.17)
cg19712490 CD81 TSS200 Low 0.43 (1.48) −0.61 (0.17)
cg12842013 HOMEZ 1stExon Low 0.39 (1.22) 0.80 (0.09)
cg01099220 LRRC14 3′UTR Low 2.09 (2.70) 1.25 (0.07)
cg25806492 SRRM1 Body Low 2.55 (2.28) 1.87 (0.07)
cg13767940 BTG4 TSS200 Low 6.40 (4.93) Data not available
cg21010178 PADI1 TSS1500 High 94.17 (5.16) Data not avaialable
cg22602019 FAM167B 3′UTR Low 13.63 (0.42) −0.26 (0.17)
cg13198133 Intergenic Intergenic High 91.00 (5.71) Data not vailable
cg02150674 PHYH TSS200 Low 0.71 (1.92) 0.73 (0.10)
aAnnotation were perfomed via IlluminaHumanMethylation450kanno.ilmn12.hg19. Homo sapiens (human) genome assembly GRCh37 (hg19)61.
bMethylation level according to iMETHYL database (low, medium, high). IMETHYL provides whole-DNA methylation (~24 million autosomal CpG sites), whole-
genome (~9 million single-nucleotide variants) and whole-transcriptome (>14 000 genes) data for CD4+ T-lymphocytes, monocytes and neutrophils collected
from ~100 subjects.
cFPKM Fragments Per Kilobase of transcript per Million mapped reads.
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limiting these concentrations to 40mg/L as CRP levels above this threshold
are most likely to be from acute bacterial infections in low- and middle-
income countries (LMIC)18.
Additional removal of participants with CRP levels >40mg/L (which were
also conspicuous outliers in the CRP distribution, Supplementary Fig. 7) led
to a final sample of 589 used in the current analyses (Supplementary Fig.
6).
Ethical approval and consent to participate
Ethical approval was obtained from ethics committees of involved
institutions in Ghana (Kwame Nkrumah University of Science & Technol-
ogy: CHRPE/AP/200/12), Netherlands (Amsterdam University Medical
Center: W12-062#12.17.0086), Germany (Charité University Berlin: EA1/
307/12) and UK (London School of Hygiene & Tropical Medicine: 6208)
before the start of data collection. All participants gave written informed
consent.
Phenotypic measurements
A standardised approach for questionnaires, anthropometric measure-
ments and venepuncture samples was used across all study sites. The
following measurements were obtained through a structured question-
naire; age, sex, location of residence, educational attainment, use of
antihypertensive medication, previously diagnosed diabetes mellitus,
alcohol consumption and smoking. Education was categorised as follows;
(1) none or elementary, (2) primary, (3) secondary and (4) tertiary. Alcohol
consumption was calculated in units/day. Smoking was categorised into
current smokers, past smokers, or non-smokers. Body mass index (BMI) was
calculated as weight (kg) divided by height in meters squared (m2). Blood
pressure was measured three times using a validated semi-automated
device (The Microlife WatchBP home) with appropriate cuffs in a sitting
position after at least 5 min rest. The mean of the last two blood pressure
measurements was used in the analyses (mmHg). Concentrations of total
blood cholesterol, low‐density lipoprotein (LDL) cholesterol and high‐
density lipoprotein (HDL) cholesterol were assessed using colorimetric test
kits (mmol/L). Fasting plasma glucose concentration (minimum overnight
fast of 8 h) was measured using an enzymatic method (hexokinase) in
mmol/L. Presence of type 2 diabetes (T2D) was defined using the WHO
diagnostic criteria (fasting glucose ≥ 7.0 mmol/L, or current use of
medication prescribed to treat T2D or self‐reported T2D). CRP was
measured using the high sensitivity immunoturbidimetric assay in mg/L.
For baseline characteristics, CRP was categorized according to American
Heart Association (AHA) categories: <1mg/L= low, 1–3mg/L= borderline,
>3mg/L= elevated. All biochemical analyses were performed in Berlin
with an ABX Pentra 400 chemistry analyser (ABX Pentra; Horiba ABX,
Germany).
DNAm processing, profiling and quality control
Assessment of the epigenetic profiles, its processing, and quality control
within the RODAM study were described previously15. In brief, bisulfite
conversion of DNA was conducted with the Zymo EZ DNA MethylationTM
kit. The converted DNA was amplified and hybridized on the Infinium®
HumanMethylation450 BeadChip, which quantifies DNAm levels of
approximately 485,000 CpG sites. Quality control was performed using
the MethylAid package in R (version 1.4.0.). Functional normalization (which
uses the internal control probes present on the array to infer between-
array technical variation) was applied using minfi package (version
3.1.0)53,54. Probes annotated to the X, and Y chromosomes, known to
involve cross hybridization or to involve a (common) SNP were removed
from the dataset, resulting in a total set of 429,459 CpG sites. Blood cell
mixture estimation was based on the method described by Houseman
et al. Bioconductor sva package was used to construct surrogate variables
for removal of unwanted variation55.
Statistical analysis
Statistical analysis was carried out using R and Bioconductor packages.
Summary statistics were presented as proportions for categorical variables
and as means (with standard deviations) or as medians (with interquartile
ranges). Linear regression analyses were performed to determine
associations between DNAm and CRP (continuous variable) using the
minfi package (version 1.34.0, DNAm are the dependent variable). Age, sex,
alcohol consumption, smoking, estimated cell types and technical effects
(hybridization batch and array position) and surrogate variables were
included as covariates in all models. We also included BMI and T2D as
covariates in the base models to account for previous RODAM reports,
which showed an enrichment for obesity and T2D15,16,56. Inflation model
fitting was evaluated using a QQ-plot (Supplementary Fig. 8). False
discovery rate (FDR) was used to correct for multiple testing. A 5% FDR was
considered statistically significant. For all DMP analyses, M values were
calculated as the log2 ratio of the intensities of methylated CpG site versus
unmethylated CpG site. Significant differences were determined based on
M values, while beta values were used for visualization57. To detect DMRs,
we fitted models similar to DMP analyses using bumphunter with a cut-off
of 0.0066 (which limits the analysis to 100 candidate regions and 0.66%
difference in delta-beta values between candidate probes) and 1000
permutations54. We considered DMRs with ≥three adjacent probes and 5%
FDR as statistically significant.
Post-hoc analyses
We performed multiple post-hoc analyses to ascertain validity of our
findings. First, we performed an in-silico replication. To achieve this, we
referred to the previous EWAS meta-analysis on CRP and performed an
independent statistical analysis on these previously reported DMPs,
employing linear regression models like our main DMP analyses7. We
assumed statistical significance at a nominal p-value of 0.05 (two-tailed).
Second, we carried out sensitivity analyses on obesity and T2D. Since
DNAm profiling in the primary RODAM study was based on obese or T2D
case-control status, we performed a sensitivity analysis to determine the
influence of BMI and T2D in the current analysis15,16. To achieve this, we
repeated the statistical procedure applied in the main analysis but
excluded BMI and T2D as covariates in the linear regression models. In
turn, we assessed whether delta-beta values and p-values ascribed to
statistically significant DMPs in main analysis were strongly correlated with
those (delta-beta values and p-values) in sensitivity analyses (linear models
excluding BMI and T2D as covariates). A Pearson’s correlation coefficient (r)
>0.80 was considered strong correlation. Additionally, we looked to
previous EWAS on obesity and T2D in the same study population and
ascertained whether our statistically significant DMPs were already
reported in those two previous studies15,16.
Third, we performed sensitivity analyses on location of residence.
Considering that Ghanaians sampled in our study were resident on two
different continents (in Ghana and in Europe). The environment in Europe
differs to that in Ghana (i.e., pollution, microbes, diet etc.), which might
distinctively affect inflammatory patterns in Ghanaian’s resident in Ghana
as compared to Ghanaians resident in Europe. We therefore assessed the
influence of location of residence on our findings. We first applied similar
statistical procedures from the main analysis to Ghanaians resident in
Ghana and Ghanaians resident in Europe separately. We then compared
the effect sizes (delta-beta values) between the two groups for the DMPs
that were statistically significant in the main analysis. Next, we repeated
the statistical procedure applied in the main analysis and included location
of residence as a covariate in the linear regression models. In turn, we
assessed whether delta-beta values and p-values for the statistically
significant DMPs in the main analysis were strongly correlated with those
(delta-beta values and p-values) from sensitivity analyses (linear models
including location of residence as a covariate). A Pearson’s correlation
coefficient (r) >0.80 was considered strong correlation.
Fourth, we examined DNAm differences at CRP levels ≤10mg/L. With
regards to chronic inflammation, CRP concentrations ≤10mg/L are usually
seen in healthy adults without chronic diseases, while those >10mg/L are
mostly seen in those with chronic diseases42,43. Since we had included CRP
concentrations up to 40mg/L in our main analysis, we also wanted to
ascertain whether DNAm variations were also detectable at CRP levels
≤10mg/L in our study population. We therefore performed a subset
analysis on participants with CRP concentrations ≤10mg/L employing
similar statistical procedures as in the main analysis.
Fifth, we investigated the link between DNAm variations in CRP and
estimated CVD risk. To achieve this, we selected statistically significant
DMPs from the main analysis and investigated their associations with 10-
year predicted CVD risk using linear regression models. Ten-year CVD risk
was estimated using the American College of Cardiology/American Heart
Association atherosclerotic cardiovascular disease (ACC/AHA ASCVD) risk
score as previously applied in RODAM study58. The risk score is used
among persons aged 40–79 years, without prior history of CVD, using an
algorithm that combines age, sex, use of antihypertensive medication,
systolic blood pressure, presence of T2D, total cholesterol, HDL cholesterol
and smoking status59. A score of >7.5% is considered to be an elevated risk
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of developing a CVD in the next 10 years based on the prior work by Goff
et al.59. We assumed statistical significance at 5% FDR. Variables that were
already part of the CVD risk score were not adjusted for in our linear
regression models.
Sixth, we ascertained biological relevance of findings with respect to gene
expression, and links to inflammation and CVD in public databases. We first
evaluated the link between statistically significant DMPs and gene expression
in the IMETHYL database50. IMETHYL provides whole-DNA, whole-genome
and whole-transcriptome data for normal CD4+ T-lymphocytes, monocytes
and neutrophils collected from ~100 healthy subjects. Next, we assessed
whether genes annotated to statistically significant DMPs were enriched to
discrete pathways in the KEGG and GO databases using MissMethyl package
at 5% FDR. Finally, we searched in GWAS catalog, GeneCards and EWAS
catalog to determine whether genes annotated to statistically significant
DMPs were linked to inflammation or CVD traits.
Reporting summary
Further information on research design is available in the Nature Research
Reporting Summary linked to this article.
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